| Literature DB >> 29086830 |
Khadijah M Al-Zaydi1, Hosam H Khalil2, Ayman El-Faham2, Sherine N Khattab3.
Abstract
BACKGROUND: Replacement of chloride ions in cyanuric chloride give several variants of 1,3,5-triazine derivatives which were investigated as biologically active small molecules. These compounds exhibit antimalarial, antimicrobial, anti-cancer and anti-viral activities, among other beneficial properties. On the other hand, treatment of bacterial infections remains a challenging therapeutic problem because of the emerging infectious diseases and the increasing number of multidrug-resistant microbial pathogens. As multidrug-resistant bacterial strains proliferate, the necessity for effective therapy has stimulated research into the design and synthesis of novel antimicrobial molecules. <br> RESULTS: 1,3,5-Triazine 4-aminobenzoic acid derivatives were prepared by conventional method or by using microwave irradiation. Using microwave irradiation gave the desired products in less time, good yield and higher purity. Esterification of the 4-aminobenzoic acid moiety afforded methyl ester analogues. The s-triazine derivatives and their methyl ester analogues were fully characterized by FT-IR, NMR (1H-NMR and 13C-NMR), mass spectra and elemental analysis. All the synthesized compounds were evaluated for their antimicrobial activity. Some tested compounds showed promising activity against Staphylococcus aureus and Escherichia coli. <br> CONCLUSIONS: Three series of mono-, di- and trisubstituted s-triazine derivatives and their methyl ester analogues were synthesized and fully characterized. All the synthesized compounds were evaluated for their antimicrobial activity. Compounds (10), (16), (25) and (30) have antimicrobial activity against S. aureus comparable to that of ampicillin, while the activity of compound (13) is about 50% of that of ampicillin. Compounds (13) and (14) have antimicrobial activity against E. coli comparable to that of ampicillin, while the activity of compounds (9-12) and (15) is about 50% of that of ampicillin. Furthermore, minimum inhibitory concentrations values for clinical isolates of compounds (10), (13), (14), (16), (25) and (30) were measured. Compounds (10) and (13) were more active against MRSA and E. coli than ampicillin. Invitro cytotoxicity results revealed that compounds (10) and (13) were nontoxic up to 250 µg/mL (with SI = 10) and 125 µg/mL (with SI = 5), respectively. Graphical abstract Three series of mono-, di- and trisubstituted s-triazine derivatives and their methyl ester analogues were synthesized and evaluated for their antimicrobial activity. Several compounds have antimicrobial activity against S. aureus and E. coli comparable to that of ampicillin.Entities:
Keywords: 1,3,5-Triazine derivatives; 4-Aminobenzoic acid; Aniline; Antimicrobial activity; Benzylamine; Diethylamine; Microwave irradiation; Morpholine; Piperidine
Year: 2017 PMID: 29086830 PMCID: PMC5423881 DOI: 10.1186/s13065-017-0267-3
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Scheme 1Synthesis of mono-, di- and trisubstituteds-triazine derivatives 3 – 18
Fig. 1Restricted rotation around C6–N bond due to resonance
Scheme 2Synthesis of tripod morpholino-s-triazine derivatives 19–22
Fig. 2Newman projection formula of N-(4-benzylamino-6-morpholino-1,3,5-triazin-2-yl) aminobenzoic acid 20
Scheme 3Synthesis of methyl ester of C2—symmetrical and morpholino 1,3,5-triazine tripod derivatives 23–31
Minimal inhibitory concentration (MIC) of test compounds in μg/mL
| Test compound |
|
|
| Test compound |
|
|
|
|---|---|---|---|---|---|---|---|
|
| 25 | 12.5 | – |
| 100 | >200 | >200 |
|
| – | – | 12.5 |
| 100 | 50 | >200 |
|
| 50 | 100 | >200 |
| 100 | 100 | >200 |
|
| 50 |
| >200 |
| 100 | 100 | >200 |
|
| 50 | 100 | >200 |
| 100 | 100 | >200 |
|
| 50 | 50 | >200 |
| 100 |
| >200 |
|
|
|
| >200 |
| 100 | 100 | >200 |
|
|
| 100 | >200 |
| 100 | 100 | >200 |
|
| 50 | >200 | >200 |
| 100 | >200 | >200 |
|
| 100 |
| >200 |
| 100 | >200 | >200 |
|
| 100 | 100 | >200 |
| 100 |
| >200 |
|
| 100 | >200 | >200 |
| 100 | 100 | >200 |
|
| >200 | 100 | >200 |
Minimum inhibitory concentrations (MIC µg/mL) for clinical isolates of compounds (10), (13), (14), (16), (25) and (30)
| Test compound |
|
|
|---|---|---|
|
| >200 | >200 |
|
|
| 100 |
|
| 100 |
|
|
| >200 | 100 |
|
| 100 | >200 |
|
| 100 | 100 |
|
| >200 | >200 |
MRSA methicillin-resistant Staphylococcus aureus
CC50 values and selectivity index (SI) of the most active compounds on normal VERO
| Test compound | (CC50)a (µg/mL) | Selectivity index (SI)b |
|---|---|---|
|
| 250 | 10 |
|
| 125 | 5 |
aCC50 is the concentration of compound required to kill 50% of the fibroblast cells
bThe selectivity index (SI) was calculated using the formula, SI = CC50/MIC